- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07559812
Comparison of Vaginal PGE2 (Dinoprostone) and Vaginal Misoprostol for Induction of Labour in Primigravid Term Pregnancy
27 april 2026 uppdaterad av: Adeel Ahmed, Mayo Hospital Lahore
This randomized controlled trial was conducted to compare vaginal misoprostol and vaginal PGE2 (dinoprostone) for induction of labour in primigravid women with term pregnancy.
Labour induction is commonly required when pregnancy reaches term but spontaneous labour has not started.
Different medicines are used to soften the cervix and start uterine contractions, but their effectiveness may vary.
A total of 240 primigravid women with singleton pregnancy at 40 weeks or more of gestation, who were not in spontaneous labour and were planned for induction of labour, were included.
Participants were allocated into two equal groups.
Women in Group M received a 50 μg vaginal misoprostol insert, while women in Group D received a 3 mg vaginal dinoprostone insert.
Both medicines were given under aseptic conditions in the inpatient obstetrics setting.
The main purpose of the study was to compare the proportion of women who achieved successful vaginal delivery after induction.
The study also assessed the time interval from first treatment to vaginal delivery among successful cases.
Additional maternal and neonatal outcomes included peripartum hemorrhage, premature rupture of membranes, and admission of the newborn to the neonatal intensive care unit within 48 hours after delivery.
Studieöversikt
Status
Aktiv, inte rekryterande
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
240
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Mayo Hospital, Lahore
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Women age 18-45 years, primigravida, undergoing induction of labour at Gestational age ≥ 40 weeks by last menstrual period (LMP)
- Not having spontaneous labor at 40 weeks of gestation by last menstrual period (LMP)
Exclusion Criteria:
- Absent fetal cardiac activity on CTG
- Non-reassuring CTG on admission
- Anomalous fetus on ante-natal ultrasound record.
- Not willing to participate.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group M Misoprostol
Participants in this group received 50 μg vaginal misoprostol insert under aseptic conditions for induction of labour.
|
50 μg misoprostol was administered as a vaginal insert for induction of labour in primigravid women with term pregnancy.
|
|
Aktiv komparator: Group D Dinoprostone
Participants in this group received 3 mg vaginal dinoprostone insert under aseptic conditions for induction of labour
|
3 mg dinoprostone was administered as a vaginal insert for induction of labour in primigravid women with term pregnancy.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Successful Vaginal Delivery
Tidsram: From first administration of the assigned vaginal insert until vaginal delivery, assessed up to 48 hours after first treatment administration.
|
Successful vaginal delivery was assessed as the proportion of participants who achieved vaginal delivery after induction of labour with the assigned study drug.
|
From first administration of the assigned vaginal insert until vaginal delivery, assessed up to 48 hours after first treatment administration.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time Interval From First Treatment to Vaginal Delivery
Tidsram: From first administration of the assigned vaginal insert until vaginal delivery, assessed up to 48 hours after first treatment administration.
|
The time interval from administration of the assigned vaginal insert to vaginal delivery was measured in hours among participants who achieved successful vaginal delivery.
|
From first administration of the assigned vaginal insert until vaginal delivery, assessed up to 48 hours after first treatment administration.
|
|
Peripartum Hemorrhage
Tidsram: From delivery until 3 days after delivery.
|
Peripartum hemorrhage was recorded as Yes when excessive blood loss was associated with both blood transfusion during or within 3 days after delivery and a fall in hemoglobin of ≥2 g/dL from baseline.
Baseline hemoglobin was measured at admission to the labour room and post-delivery hemoglobin was assessed 48 hours after delivery.
|
From delivery until 3 days after delivery.
|
|
Neonatal Intensive Care Unit Admission
Tidsram: Within 48 hours after delivery.
|
Neonatal intensive care unit admission was assessed as the proportion of newborns admitted to the neonatal intensive care unit after delivery.
|
Within 48 hours after delivery.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Saher Anam, Mayo Hospital Lahore
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
29 oktober 2025
Primärt slutförande (Beräknad)
29 april 2026
Avslutad studie (Beräknad)
29 april 2026
Studieregistreringsdatum
Först inskickad
21 april 2026
Först inskickad som uppfyllde QC-kriterierna
27 april 2026
Första postat (Faktisk)
30 april 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
30 april 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
27 april 2026
Senast verifierad
1 april 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Mayo5
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .